Abstract
CD73: A Promising Biomarker in Cancer Patients.
Highlights
Over the past years, the adenosine pathway has become a topic of great interest in cancer research, due to an increasing number of evidences showing its role in tumor progression and metastases
The classical pathway of extracellular adenosine production is based on sequential reactions mediated by two ectonucleotidases, extracellular adenosine triphosphate is first hydrolyzed by CD39 into adenosine monophosphate (AMP) and dephosphorylated into adenosine by CD73
The purinergic signaling plays a critical role in cancer, since adenosine triphosphate is released in the tumor microenvironment upon hypoxia, nutrient starvation, cell death, or treatment with some chemotherapeutic agents
Summary
The adenosine pathway has become a topic of great interest in cancer research, due to an increasing number of evidences showing its role in tumor progression and metastases. A large number of preclinical studies have investigated the role of CD73 in immunosuppression and tumor progression, proving that the inhibition of CD73 is an effective immunotherapeutic strategy for different types of cancers. Various studies have explored the significance of CD73 expression and activity in cancer patients, evaluating possible correlations with survival and/or clinical response.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
